Search Results - "DiPeri, Timothy P"

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer by Saridogan, Turcin, Akcakanat, Argun, Zhao, Ming, Evans, Kurt W., Yuca, Erkan, Scott, Stephen, Kirby, Bryce P., Zheng, Xiaofeng, Ha, Min Jin, Chen, Huiqin, Ng, Patrick K. S., DiPeri, Timothy P., Mills, Gordon B., Rodon Ahnert, Jordi, Damodaran, Senthil, Meric-Bernstam, Funda

“…Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as…”
Get full text

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan by Zhao, Ming, DiPeri, Timothy P., Raso, Maria Gabriela, Zheng, Xiaofeng, Rizvi, Yasmeen Qamar, Evans, Kurt W., Yang, Fei, Akcakanat, Argun, Roberto Estecio, Marco, Tripathy, Debu, Dumbrava, Ecaterina E., Damodaran, Senthil, Meric-Bernstam, Funda

“…TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2…”
Get full text

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma by DiPeri, Timothy P, Demirhan, Mehmet, Karp, Daniel D, Fu, Siqing, Hong, David S, Subbiah, Vivek, Lim, Joann, Ballester, Leomar Y, Tayar, Jean H, Suarez-Almazor, Maria E, Javle, Milind, Meric-Bernstam, Funda

“…Intrahepatic cholangiocarcinoma is a rare malignancy, which is rich in actionable alterations. Genomic aberrations in the mitogen-activated protein kinase…”
Get full text

Total neoadjuvant therapy for locally advanced gastric cancer: too much of a good thing? by DiPeri, Timothy P, Gong, Jun, Burch, Miguel

Get full text

Socioeconomic disparities in patients with small bowel neuroendocrine tumors by DiPeri, Timothy P., Manguso, Nicholas, Gong, Jun, Atkins, Katelyn M., Hendifar, Andrew E., Gangi, Alexandra

“…Abstract Background and Objectives Demographic and socioeconomic disparities affect cancer specific outcomes in numerous malignancies, but the impact of these…”
Get full text

Next generation sequencing for biliary tract cancers by DiPeri, Timothy P, Javle, Milind M, Meric-Bernstam, Funda

Get more information

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers by DiPeri, Timothy P, Evans, Kurt W, Raso, Maria Gabriela, Zhao, Ming, Rizvi, Yasmeen Q, Zheng, Xiaofeng, Wang, Bailiang, Kirby, Bryce P, Kong, Kathleen, Kahle, Michael, Yap, Timothy A, Dumbrava, Ecaterina E, Ajani, Jaffer A, Fu, Siqing, Keyomarsi, Khandan, Meric-Bernstam, Funda

“…Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted…”
Get full text

Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer by DiPeri, Timothy P., Evans, Kurt W., Scott, Stephen, Zheng, Xiaofeng, Varadarajan, Kaushik, Kwong, Lawrence N., Kahle, Michael, Tran Cao, Hop S., Tzeng, Ching-Wei, Vu, Thuy, Kim, Sunhee, Su, Fei, Raso, Maria Gabriela, Rizvi, Yasmeen, Zhao, Ming, Wang, Huamin, Lee, Sunyoung S., Yap, Timothy A., Rodon, Jordi, Javle, Milind, Meric-Bernstam, Funda

“…Abstract Purpose: Biliary tract cancers (BTCs), which are rare and aggressive malignancies, are rich in clinically actionable molecular alterations. A major…”
Get full text

Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma by DiPeri, Timothy P., Zhao, Ming, Evans, Kurt W., Varadarajan, Kaushik, Moss, Tyler, Scott, Stephen, Kahle, Michael P., Byrnes, Charnel C., Chen, Huiqin, Lee, Sunyoung S., Halim, Abdel-Baset, Hirai, Hiroshi, Wacheck, Volker, Kwong, Lawrence N., Rodon, Jordi, Javle, Milind, Meric-Bernstam, Funda

“…There is a knowledge gap in understanding mechanisms of resistance to fibroblast growth factor receptor (FGFR) inhibitors (FGFRi) and a need for novel…”
Get full text

Discordance of HER2 Expression and/or Amplification on Repeat Testing by DiPeri, Timothy P, Kong, Kathleen, Varadarajan, Kaushik, Karp, Daniel D, Ajani, Jaffer A, Pant, Shubham, Press, Michael F, Piha-Paul, Sarina A, Dumbrava, Ecaterina E, Meric-Bernstam, Funda

“…We sought to assess discordance of HER2 status in patients with HER2-amplified/expressing solid tumors who underwent reevaluation of HER2 status. Patients with…”
Get full text

Prospective Implementation of Standardized Post-Hepatectomy Care Pathways to Reduce Opioid Prescription Volume after Inpatient Surgery by DiPeri, Timothy P, Newhook, Timothy E, Arvide, Elsa M, Dewhurst, Whitney L, Bruno, Morgan L, Chun, Yun Shin, Tran Cao, Hop S, Lee, Jeffrey E, Vauthey, Jean-Nicolas, Tzeng, Ching-Wei D

“…Among the goals of prospectively implemented post-hepatectomy care pathways was a focus on patient-centric opioid reduction. We sought to evaluate the impact…”
Get full text

Elevated DNA Oxidation and DNA Repair Enzyme Expression in Brain White Matter in Major Depressive Disorder by Szebeni, Attila, Szebeni, Katalin, DiPeri, Timothy P., Johnson, Luke A., Stockmeier, Craig A., Crawford, Jessica D., Chandley, Michelle J., Hernandez, Liza J., Burgess, Katherine C., Brown, Russell W., Ordway, Gregory A.

“…Abstract Background: Pathology of white matter in brains of patients with major depressive disorder (MDD) is well-documented, but the cellular and molecular…”
Get full text

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts by DiPeri, Timothy P, Evans, Kurt W, Wang, Bailiang, Zhao, Ming, Akcakanat, Argun, Raso, Maria Gabriela, Rizvi, Yasmeen Q, Zheng, Xiaofeng, Korkut, Anil, Varadarajan, Kaushik, Uzunparmak, Burak, Dumbrava, Ecaterina E, Pant, Shubham, Ajani, Jaffer A, Pohlmann, Paula R, Jensen, V Behrana, Javle, Milind, Rodon, Jordi, Meric-Bernstam, Funda

“…Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of…”
Get more information

Prognostic significance of preoperative and postoperative CA 19‐9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first by DiPeri, Timothy P., Newhook, Timothy E., Prakash, Laura R., Ikoma, Naruhiko, Maxwell, Jessica E., Kim, Michael P., Lee, Jeffrey E., Katz, Matthew H. G., Tzeng, Ching‐Wei D.

“…Background Normal(ization) of serum carbohydrate 19‐9 (CA19‐9) before/after surgery has not been compared in patients with pancreatic adenocarcinoma (PDAC)…”
Get full text

Opioid Discharge Prescriptions After Inpatient Surgery: Risks of Rebound Refills by Length of Stay by DiPeri, Timothy P., Newhook, Timothy E., Tran Cao, Hop S., Ikoma, Naruhiko, Dewhurst, Whitney L., Arvide, Elsa M., Bruno, Morgan L., Katz, Matthew H.G., Vauthey, Jean-Nicolas, Lee, Jeffrey E., Tzeng, Ching-Wei D.

“…As inpatient stays become shorter, one concern with standardizing discharge opioid prescriptions is the potential risk of “rebound refills.” We sought to…”
Get full text

Impact of palliative therapies in metastatic esophageal cancer patients not receiving chemotherapy by Kim, Sungjin, DiPeri, Timothy P, Guan, Michelle, Placencio-Hickok, Veronica R, Kim, Haesoo, Liu, Jar-Yee, Hendifar, Andrew, Klempner, Samuel J, Nipp, Ryan, Gangi, Alexandra, Burch, Miguel, Waters, Kevin, Cho, May, Chao, Joseph, Atkins, Katelyn, Kamrava, Mitchell, Tuli, Richard, Gong, Jun

Get full text

Prognostic significance of serum CA 19-9 response and dynamics in patients with intrahepatic cholangiocarcinoma undergoing surgical resection by DiPeri, Timothy P., Newhook, Timothy E., Tzeng, Ching-Wei D., Chun, Yun Shin, Lee, Sunyoung S., Javle, Milind M., Vauthey, Jean-Nicolas, Tran Cao, Hop Sanderson

“…Abstract only 479 Background: Pre and post-operative elevation of serum CA 19-9 have been associated with poor outcomes and increased risk of recurrence in…”
Get full text

Repeat large panel genomic sequencing identifies actionable alterations and characterizes the genomic landscape in patients with metastatic solid tumors by Coleman, Niamh, DiPeri, Timothy P., Nguyen, Daniel, Naing, Aung, Piha-Paul, Sarina Anne, Tsimberidou, Apostolia Maria, Zheng, Xiaofeng, Johnson, Amber, Wang, Wanlin, Shaw, Kenna R., Dumbrava, Ecaterina Elena, Fu, Siqing, Rodon Ahnert, Jordi, Hong, David S., Subbiah, Vivek, Yap, Timothy A., Luthra, Rajyalakshmi, Patel, Keyur P., Meric-Bernstam, Funda

“…3076 Background: The implementation of genomic profiling with next generation sequencing has revolutionized the field of precision oncology. Comprehensive…”
Get full text

Abstract 327: Antitumor efficacy of trastuzumab deruxtecan in combination with adavosertib in HER2-expressing Cyclin E amplified gastroesophageal cancers by DiPeri, Timothy P., Evans, Kurt W., Raso, Gabriela, Rizvi, Yasmeen Q., Zheng, Xiaofeng, Kirby, Bryce, Kong, Kathleen, Keyomarsi, Khandan, Ajani, Jaffer A., Yap, Timothy A., Meric-Bernstam, Funda

“…Abstract Purpose: Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody-drug conjugate approved for patients with HER2-positive gastric/gastroesophageal…”
Get full text

Abstract 1791: Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan by Zhao, Ming, DiPeri, Timothy P., Raso, Gabriela, Rizvi, Yasmeen Q., Zheng, Xiaofeng, Evans, Kurt, Akcakanat, Argun, Yang, Fei, Tripathy, Debu, Dumbrava, Ecaterina Ileana, Damodaran, Senthil, Meric-Bernstam, Funda

“…Abstract Purpose: TROP2 is overexpressed in many tumor types and is being actively pursued as a target. Sacituzumab govitecan (SG), a humanized anti-TROP2…”
Get full text